According to new research, when the skin of a small group of adults and children with eczema was coated with live bacteria from the skin of healthy individuals, the severity of symptoms and need for medication for most of the patients declined significantly.
pic: pexels.com

New research suggests an unusual new approach that might change things for those who suffer from eczema: applying live bacteria from healthy people to our skin.

According to research by the National Institute of Allergy and Infectious Diseases, when the skin of a small group of adults and children with eczema was coated with live Roseomonas mucosa bacteria from the skin of healthy individuals, the severity of symptoms and need for medication for most of the patients declined significantly.

“I only saw participants twice, when they first came in and when they were done. Some looked like completely different people,” said Ian Myles, lead author of the early-stage study. “We’re already seeing strong results with one species of one bacterium. [The therapy] is only going to get more nuanced and more refined.”

Eczema, or atopic dermatitis, occurs when the skin doesn’t function normally. It doesn’t retain water well and allows bad bacteria to flourish and enter the body, causing a surge of inflammation that can lead to dry, flaky and inflamed skin, said Joseph Fowler , a clinical professor of dermatology at the University of Louisville, who was not involved in the study. It is also linked to an increased risk for other allergic conditions, such as hay fever and asthma, according to the National Institutes of Health.

The telltale rashes associated with atopic dermatitis typically appear in infants and children, and approximately half outgrow the condition by puberty. For a small percentage of individuals, symptoms first appear in adulthood. Overall, women are more prone to the condition than men, and multiracial, white and Asian individuals experience it at a higher rate than others.

There is no known cure. Most treatments – such as topical steroidal and nonsteroidal ointments, antihistamines, antibiotics and immune suppressors – decrease the intensity of symptoms and the number of outbreaks, but they don’t address the root cause of the condition, according to Fowle. Rather, they offer temporary, slow-acting relief, and they can be expensive.

While there’s disagreement within the research community whether eczema is the result of genetics or something in the environment, scientists have begun to pay closer attention to the microorganisms living on the skin, or the skin’s microbiome.

According to the National Institutes of Health, the skin of people affected by eczema tends to have a lot of a type of bacteria – Staphylococcus aureus – that can both cause skin infections and trigger immune responses that increase inflammation and worsen symptoms.

“Bacteria on the skin tend to live in harmony. For people with eczema, however, the bacteria tends to get out of whack and out of balance,” Fowler said.

Researchers noticed a pattern between where eczema occurs on the body and the types of microbes present – or absent – in that area, suggesting that the ecosystem of bacteria on the skin plays a role in development of the skin condition.

By restoring the balance of good and bad organisms of the skin microbiome, they hope to improve the skin’s barrier function and short-circuit the body’s immune response.

For the first part of the new study, NIAID researchers enrolled 10 adults with atopic dermatitis.

For six weeks, they received twice-weekly treatments of R. mucosa from healthy skin, sprayed on their inner elbows and one other area of their choice where eczema typically showed up or was severe. Studies in mice and on human skin cells had shown that R. mucosa could alleviate signs of eczema. Participants continued their regular eczema treatments such as topical ointments and medication.

A second part of the study looked at young people, enrolling five children between the ages of 9 and 14 with eczema. They received twice-weekly R. mucosa treatments for 12 weeks, followed by every-other-day treatment for another four weeks. After the treatment period, researchers continued to assess the treatment effect.

Myles says he wasn’t expecting to see a big difference, especially among adult participants. Yet, six of the 10 adults and four of the five children experienced a greater than 50 percent improvement in the severity of their symptoms and a decrease in S. aureus bacteria, the overgrowth of which is believed to worsen eczema symptoms. Most decreased their use of steroid creams and treatments, and their quality of life improved, too. The adults continued to see a benefit nine months after treatment.

“The hope is that by manipulating the bacteria on the skin, we can make people better and the bacteria will stay in place and continue to provide a therapeutic benefit,” said Myles.

“This potential treatment is really interesting because it doesn’t involve using medication and may be less expensive,” says Fowler.

Myles says he and his NIAID colleagues will now expand the study to more children and adults, and will examine the DNA of all volunteers to see whether there’s a genetic reason why participants did or did not respond to treatment.

- Advertisement -